Takayasu Kurata

发表

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Kazuko Sakai, Taroh Satoh, Kazuhiko Nakagawa, 2011, Biochemical and biophysical research communications.

A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer

Yuichi Takiguchi, Hirofumi Mukai, Nobuyuki Yamamoto, 2013, PloS one.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Thomas John, Aleksandra, Aleksandra Markovets, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.